Medication info
Rosunex Tablet 5mg (Rosuvastatin Calcium)

Rosunex Tablet 5mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201706842 · Approved 2017.08.27 · Insurance code 643104380

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to the maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years) Aged 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. The safety and efficacy in children younger than 10 years have not been established.

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • coronary heart disease
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is primarily used as an adjunct therapy in patients with primary hypercholesterolemia and mixed hyperlipidemia that cannot be controlled by diet and exercise alone. It is also used in patients with homozygous familial hypercholesterolemia together with dietary therapy or other lipid-lowering therapies to effectively lower cholesterol levels. For patients with hypercholesterolemia, this drug helps reduce total cholesterol and LDL cholesterol levels to goal levels, thus delaying the progress of atherosclerosis. Particularly, for pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, it serves as an adjunct to diet to lower LDL cholesterol and Apo-B levels. Additionally, it is used as an adjunct therapy in patients with primary dysbetalipoproteinemia and contributes to the reduction of the risk of stroke, myocardial infarction, and arterial revascularization in middle-aged and older adults at high risk for cardiovascular diseases. Overall, this medication is used to improve hyperlipidemia and cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to the maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years) Aged 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. The safety and efficacy in children younger than 10 years have not been established.

Precautions

This drug should not be used in certain patients. For example, patients who are allergic to this drug, have severely impaired liver function, have muscle disease, or have greatly reduced kidney function should not use this medication. Additionally, it is recommended that pregnant or breastfeeding women, and fertile women not using adequate contraception avoid this medication. Patients at high risk for myopathy or rhabdomyolysis, such as those with moderate to severe renal dysfunction, hypothyroidism, a family history or those who are alcoholics should also avoid high doses of this medication. This drug can affect liver function, so patients with a history of liver disease or heavy alcohol consumption should undergo liver function tests before administration and regularly monitor liver enzymes during treatment. If symptoms such as muscle pain or weakness appear, healthcare professionals should be notified immediately, and blood tests may be necessary to check for muscle damage. Furthermore, this medication may slightly increase blood glucose levels; thus, patients at risk for diabetes should regularly check their blood glucose and HbA1c levels. This drug may interact with other medications, especially when taken with certain antiviral agents, immunosuppressants, antibiotics, and fibrate-class drugs, so caution is warranted. When used in combination, the risk of muscle-related adverse reactions may increase, so consultation with healthcare professionals is advised. During pregnancy or breastfeeding, it is safest not to use this medication, and women of childbearing age must use proper contraceptive methods. In cases of overdose, as there is no specific antidote, treatment should be symptomatic, and monitoring of liver function and muscle enzyme levels is necessary. Dizziness may occur when driving or operating machinery, so caution is required. Finally, this medication may rarely cause serious skin reactions, liver function abnormalities, or muscle damage in some patients; any unusual symptoms should be reported to healthcare professionals immediately, and treatment should be discontinued.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegic myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptom complex drug reaction syndrome, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, amnesia, dissociative amnesia, memory impairment, confusion, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, widespread pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from exposure to air or moisture. It is advised to maintain the storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.